Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

Tongji ,Sichuan ,China ,United States ,Taiwan ,Huazhong ,Hubei ,Hong Kong ,Suzhou ,Jiangsu ,Austria ,Vienna ,Wien ,Macau ,Innovent Biologics ,Equecabtagene Autoleucel Chi ,Adimab Incyte ,Equecabtagene Autoleucel ,Chunrui Li ,Eli Lilly ,Equecabtagene Autoleucel Innovent ,European Hematology Association ,Md Anderson Cancer Center ,China National Medical Products Administration ,Huazhong University Of Science Technology ,Department Of Hematology ,Innovent Or Company ,Incyte Corporation ,Huazhong University Of Science ,Prnewswire Innovent Biologics Inc ,Drug Administration ,Tongji Medical College ,Tongji Hospital Of Medical College ,Office Of Orphan Products Development ,Innovent Biologics Inc ,Annual Meeting ,Updated Phase ,Refractory Multiple ,Tongji Hospital ,Huazhong University ,Multiple Myeloma ,Therapy Designation ,Drug Designation ,Orphan Products Development ,New Drug Application ,Refractory Multiple Myeloma ,Neuromyelitis Optica Spectrum Disorder ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,National Medical Products Administration ,Orphan Drug Designation ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Trade Show News ,Clinical Trials Amp Medical Discoveries ,